Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective

OBJECTIVE: This study aimed to estimate the cost-effectiveness of direct-acting antivirals (DAAs) among patients with non-genotype 1 for the eradication of hepatitis C virus (HCV) infection in China. METHODS: A decision-analytic Markov model was developed to estimate the lifetime costs, quality-adju...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xia, Zhao, Jingyu, Yang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703443/
https://www.ncbi.nlm.nih.gov/pubmed/33246983
http://dx.doi.org/10.1136/bmjgh-2020-003194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703443/
https://www.ncbi.nlm.nih.gov/pubmed/33246983
http://dx.doi.org/10.1136/bmjgh-2020-003194

Ejemplares similares